Worldwide: As Biosimilars Enter The US Market, Will They Be Used, And Can They Reduce Spending?

This week's blog is by Tomas Croisier and James Forsyth, a partner and director in our life sciences consulting practice, respectively. It was first featured in a blog post on the US Center of Health Solutions site, and explores the impact of biosimilars may have on the treatment of oncology, particularly in the US.1

Last autumn, the US's Food and Drug Administration (FDA) approved the first biosimilar to treat multiple types of cancer. While biosimilars have tremendous potential, there also is a good bit of uncertainty around them, particularly in oncology where biologics can have a predominant role in treatment.

February was National Cancer Prevention Month, which gave us a nice opportunity to explore the role biosimilars could play in preventing and treating cancer.2 Many biologics will lose patent protection in the US relatively soon, signalling the start of what some in the industry have dubbed, the "biologics patent cliff."

While 2018 is expected to be a big year for biosimilars in the US, a number of important issues likely need to be resolved. These issues are related and many fall under one broad question: How will biosimilars impact patient treatment and outcomes, particularly in oncology?

We should explore the following topics to better understand the role biosimilars might play in cancer treatment:

  • Treatment: How will payers and/or providers incorporate biosimilars into treatment pathways? And will biosimilars become a first-line treatment in oncology? Theoretically, physicians and payers might be more willing to use biosimilars in the second or first lines of treatment if they cost less than biologics. In the US however, oncology treatment has traditionally been guided by clinical data first, with cost as a secondary consideration. We don't anticipate price will cause a significant change in treatment patterns as a result—particularly if the originator product is already established.
  • Innovation: Biosimilars could help push innovation forward in oncology. At least on paper, greater adoption of biosimilars in oncology could free up resources in the health care system. At this point, however, it is unclear whether health systems and health care providers would use any savings to adopt next-generation oncology treatments, or if biosimilars would be used to reduce overall health care spending. The Biologics Price Competition and Innovation Act, which was enacted in 2010, sought to simplify the licensing process for biosimilars. The intent of the law was to bend the cost curve and take costs out of the system, not to spur innovation.
  • Pricing and reimbursement: How low might prices go, and how quickly? There are a lot of numbers being tossed around when it comes to the savings that biosimilars could generate. In Europe, costs for biosimilars are anywhere from 20 percent to 65 percent lower than biologics depending on the specific therapeutic area and country. The US Centers for Medicare and Medicaid Services (CMS) has guidelines for biosimilar reimbursement for Medicare, but many of the rules are not easily understood, which could hinder wider adoption. Under the rules, providers will receive identical reimbursement whether a biologic or biosimilar is prescribed.3 This means there is no financial incentive (or disincentive) for physicians to use lower-priced biosimilars.
  • Uptake: What sort of uptake can we expect for biosimilars in the US market? Uptake has varied widely—by product and therapeutic area—in European countries. At some point, biosimilars will probably overtake originator products, just as generics did in the drug market. However, the speed of this conversion remains one of the great uncertainties. Oncology in particular poses greater uncertainty than other therapeutic areas due to the number of extrapolated indications associated with some of the biosimilar products.4 Health plans could institute quotas/episodic payments to encourage physicians to use the less costly biosimilars before other biologics. In this scenario, there would be a fixed reimbursement regardless of the patient's course of treatment. Physicians, however, tend to be cautious about prescribing biosimilars. Those who are comfortable prescribing biologics might not want to switch a patient to a biosimilar until there is more experience with it.
  • Safety: How will regulators approach biosimilars? They are still in their infancy in the US, and there is still speculation about their future. While regulators are working to streamline the approval process to get biosimilars to market more quickly, the regulatory pathway is still being defined and details are limited.
  • Go-to-market: What will be the most successful way to take biosimilars to market? The European Union (EU) is where biosimilars are playing out first, and they have been on the market for about a decade. The launch of biosimilars follows the introduction of innovative drugs and generic drugs. Will the go-to-market model in the US lean more toward innovative drugs or generic drugs? Neither model has consistently proven successful in the EU.
  • Originator's response: There is broad agreement that biosimilars will compete primarily on price, though it is unclear how low those prices will go. The originator manufacturer might choose to maintain the original product premium while risking market share to the new biosimilar. Or, originator manufacturers could choose to reduce the price of their original product to parallel the biosimilar price. It might then ask customers why they would consider a biosimilar when they can have the original biologic for the same price.

Biosimilars could alter the oncology landscape
Most countries are trying to reduce public spending and improve patient health. Will biosimilars be a part of this strategy? As we reflect on National Cancer Prevention Month, it is clear that biosimilars can have the potential to reshape oncology treatment but clearly significant uncertainty remains.

Stay tuned: We intend to explore and clarify some of this uncertainty in upcoming blogs over the coming months.



3 Once the average sales price is established, Medicare payments will likely combine the biosimilar's average sales price (ASP) with a surcharge of between 4-to-6 percent of the reference product. For a biologic with a $1,000 ASP, Medicare would pay $1,060 if the surcharge is 6 percent. That would result in a $60 margin and a 6 percent margin rate. If the ASP of this biologic's biosimilar is $800, reimbursement will be at $860 ($800 + [$1000 × 6%]). This still translates to a $60 margin, but a margin rate of 7.5%.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions